

## Combined Shareholders' Meeting of June 1, 2012

### Availability of preparatory documentation for the Shareholders' Meeting

**Paris (France), May 4, 2012** – The Shareholders of the Company are invited to participate in the Combined Shareholders' Meeting of Ipsen SA to be held on Friday June 1, 2012 at 3 pm (Paris time) at La Maison des Arts et Métiers (salon La Rochefoucauld), 9 bis avenue d'Iéna, 75116 Paris, France.

The preliminary notice of meeting containing the agenda and the proposed resolutions has been published in the *Bulletin des Annonces Légales et Obligatoires* (BALO) dated April 6, 2012 and the notice of meeting has been published in the BALO and in the legal newspaper "Les Petites Affiches" dated May 4, 2012. These notices are available on Ipsen's website at the following address: [www.ipsen.com](http://www.ipsen.com).

Documents and information relating to this Meeting will be made available to shareholders under the conditions provided for by legal and regulatory provisions in force.

In accordance with applicable regulatory provisions:

- Registered shareholders can, until the fifth day (inclusive) before the Meeting, request from the Company supply of the said documents, including at their request, by way of an electronic mail. For holders of bearer shares, the exercise of this right is subject to the presentation of a certificate of attendance in the bearer share accounts kept by the empowered intermediary;
- All shareholders can consult these documents at the Company's headquarters.

#### About Ipsen

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport<sup>®</sup>, endocrinology / Somatuline<sup>®</sup>, uro-oncology / Decapeptyl<sup>®</sup> and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500 employees. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit [www.ipsen.com](http://www.ipsen.com).

#### For further information:

*Media*

##### **Didier Véron**

Vice-President, Public Affairs and Corporate Communications

Tel.: +33 (0)1 58 33 51 16

Fax: +33 (0)1 58 33 50 58

Email: [didier.veron@ipsen.com](mailto:didier.veron@ipsen.com)

*Financial Community*

##### **Pierre Kemula**

Vice-President, Investor Relations

Tel.: +33 (0)1 58 33 60 08

Fax: +33 (0)1 58 33 50 63

Email: [pierre.kemula@ipsen.com](mailto:pierre.kemula@ipsen.com)

##### **Stéphane Durant des Aulnois**

Investor Relations Manager

Tel.: +33 (0)1 58 33 60 09

Fax: +33 (0)1 58 33 50 63

Email: [stephane.durant.des.aulnois@ipsen.com](mailto:stephane.durant.des.aulnois@ipsen.com)